Frontiers | Editorial: New molecular targets for personalized treatment for low‑grade non‑Hodgkin lymphoma
The therapeutic landscape of low‑grade non‑Hodgkin lymphoma (LG‑NHL) has evolved considerably over the past decade, driven by advances in molecular biology, genomic profiling, and cancer immunology.
The editorial reviews the evolution of therapeutic strategies in low‑grade non‑Hodgkin lymphoma (LG‑NHL), highlighting recent advances in targeted therapies, immune‑based approaches, and biomarker‑driven risk stratification. It summarizes six linked contributions—ranging from mechanistic studies of EZH2/PD‑L1 dual inhibition to clinical reports of bispecific antibodies in CNS lymphoma—and underscores the importance of molecular profiling, resistance biology, and prognostic modeling for truly personalized disease management.
In LG‑NHL, the shift toward precision medicine—guided by specific genomic alterations and immune‑microenvironment signatures—offers the potential to improve treatment efficacy, reduce toxicity, and overcome resistance that traditionally limits long‑term disease control.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia